Generic drugmakers Teva and Glenmark recently became the sixth and seventh drugmakers to resolve criminal charges as a result of the DOJ’s yearslong investigation into generic drug price fixing. The settlement agreement requires both companies to pay hefty fines as well as divest their drug lines for pravastatin, a widely used statin that lowers cholesterol.
The post Teva, Glenmark To Pay $255M, Divest Cholesterol Drug To Settle DOJ Price Fixing Charges appeared first on Above the Law.
from Above the Law https://ift.tt/vhT9H7P
via IFTTT